Navigation Links
Tarix Pharmaceuticals' Peptide Technology Stimulates Revascularization Following Ischemia

CAMBRIDGE, Mass., March 5, 2013 /PRNewswire/ -- Tarix Pharmaceuticals, a biopharmaceutical company focused on developing novel, peptide-based therapies to treat a range of critical medical conditions, today announced it has uncovered a new role for its therapeutic peptides in stimulating revascularization following ischemia. 

In models of ischemic stroke and peripheral vascular disease, treatment with either the Company's natural peptide, TXA127, or its cyclic analog, PanCyte, resulted in increased blood flow and histologic evidence of vasculogenesis (new blood vessel formation).

Rick Franklin , CEO of Tarix Pharmaceuticals, stated, "We explored the therapeutic value of our peptides following ischemia, due to their stimulatory effect on endothelial progenitor cells, which are increased naturally during ischemia and play an important role in vascular regeneration.  We were very pleased, and somewhat surprised, at the efficacy seen in these models in which we saw a return to near-normal blood flow that correlated with histologic evidence of new vessel formation. In addition, in multiple models of ischemic stroke recovery, there was significant improvement in a variety of clinically relevant neurologic measurements."

Franklin continued, "Given this compelling data, we are now planning to initiate clinical trials in ischemic stroke and peripheral vascular disease in 2013."

The transient middle cerebral artery occlusion stroke model involved fifteen animals per treatment group, and was randomized and blinded. There were significant improvements in neurologic score, forelimb placement, stepping test and body swing test, all of which are standard measurements of functional response in stroke. Treatment was begun twenty-four hours after the stroke, and positive results were detectable within two weeks, and improvement continued throughout the seven-week study. In addition, there was a substantial increase in cerebral blood flow and histologic evidence of new blood vessel formation.

Separately, in a mouse model of unilateral hindlimb ischemia, ischemic recovery was compared between TXA127 or PanCyte treatment versus control animals.  Blood flow in treated animals improved significantly faster toward normal, with percent blood flow more than double that of control animals by day 49 (~85% vs ~40%).  Histologic examination again showed a significant increase in the number of functional blood vessels amongst treated animals compared to controls.

About Tarix Pharmaceuticals
Tarix Pharmaceuticals is a biopharmaceutical company focused on developing novel, peptide-based therapies to treat a range of critical medical conditions.  Tarix' proprietary technology platform consists of TXA127, a pharmaceutical formulation of the naturally occurring peptide, Angiotensin (1-7), and PanCyte, a cyclic analogue of TXA127 with an extended half-life.  TXA127 and PanCyte have shown striking effects in models of ischemic stroke and peripheral vascular disease through improvement in endothelial progenitor cell number and function. The peptides have also been effective in models of diabetes. Tarix intends to initiate clinical trials in these indications during 2013, adding to its clinical pipeline that includes multiple programs in hematopoiesis.For Tarix Pharmaceuticals:

Media / Investor Contacts:Rick Franklin

Jason Rando / Claire Sojda

Tiberend Strategic Advisors,

SOURCE Tarix Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Unigene and Tarix Pharmaceuticals Report Highly Increased Oral Bioavailability of "Peptelligence-engineered" TXA127
2. Unigene and Tarix Pharmaceuticals Enter Definitive Licensing Agreement for "Peptelligence-Engineered" TXA127
3. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
4. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
5. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
6. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
7. Icahn Issues Statement Regarding Amylin Pharmaceuticals
8. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
9. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
10. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
11. Jazz Pharmaceuticals Announces First Quarter 2012 Financial Results Conference Call On May 8, 2012
Post Your Comments:
(Date:6/23/2016)... -- Bracket , a leading clinical trial technology and ... platform, Bracket eCOA (SM) 6.0, at the 52 nd ... 2016 in Philadelphia , Pennsylvania.  A demonstration ... of its kind to fully integrate with RTSM, will be ... is a flexible platform for electronic clinical outcomes assessments that ...
(Date:6/23/2016)... , June 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new affiliate with ... Latin America . ... ... ... ...
(Date:6/23/2016)... 2016 The vast majority of dialysis patients ... Treatments are usually 3 times a week, with treatment ... travel time, equipment preparation and wait time.  This regimen ... for patients who are elderly and frail.  Many elderly ... rehabilitation centers for some duration of time. ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... 27, 2016 , ... TherapySites, the leading website ... Tennessee Counseling Association. This new relationship allows TherapySites to continue to ... adding exclusive benefits and promotional offers. , "TCA is extremely excited about this ...
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... recently ... of Eyeglasses . , Millions of individuals in the United States and Canada ... become a way to both correct vision and make a fashion statement. Even celebrities ...
(Date:6/26/2016)... ... June 26, 2016 , ... Pixel Film Studios Released ProSlice Levels, a Media ... give their videos a whole new perspective by using the title layers in ... Studios. , ProSlice Levels contains over 30 Different presets to choose from. ...
(Date:6/26/2016)... ... June 26, 2016 , ... ... have been diagnosed with endometriosis. These women need a treatment plan to not ... comprehensive approach that can help for preservation of fertility and ultimately achieving a ...
(Date:6/25/2016)... , ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library on ... Observer , brings up a new, often overlooked aspect of head lice: the parasite’s ability ... fumigation is not a common occurrence, but a necessary one in the event that lice ...
Breaking Medicine News(10 mins):